Create Medicines secured $122 million in a Series B financing to advance therapies using mRNAs delivered via liquid nanoparticles to express CARs in multiple immune-cell types inside patients. The company said the cash extends funding through 2028 and will support four clinical programs expressing CARs targeting TROP2, GPC3, HER2 and HER2 x TROP2. Create also outlined a longer-term immunology strategy to deplete B cells in autoimmune diseases, with plans to enter the clinic in 2026. The financing highlights investor appetite for platform-driven, in vivo gene expression strategies rather than ex vivo cell engineering. Near-term clinical readouts will likely determine how quickly the platform can translate potency and durability into repeatable safety profiles across different targets.